Archive: 2 12 2015
A new targeted combination therapy with potential to eliminate relapsed chronic …
Vienna, June 12, 2015 – Promising results from an early phase trial combining the anti-bcl-2 drug Venetoclax with Rituximab to eliminate CLL are presented by Dr Andrew Roberts.
Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe
Vienna, June 12, 2015 – On behalf of the EUTOS network, Dr Hoffmann will present data of a web-based registry of newly diagnosed CML patients.
Adding elotuzumab to standard treatment for multiple myeloma significantly reduc…
Vienna, June 12, 2015 – On behalf of the ELOQUENT-2 investigators, Dr Dimopoulos will present the positive results on Elotuzumab with Lenalidomide from a phase III study in patients with multiple myeloma.
Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresis…
Vienna, June 12, 2015 –Dr Guryanova will present a new mechanism for chemoresistance in AML based on acquired DNA mutations.
New GFI1B variants in bleeding and platelet disorders
Vienna, June 12, 2015 –Dr Marneth will discuss the findings of eight new genetic variants in GFI1B that have been discovered in patients with bleeding and platelet disorders and consequences for new therapeutic targets.
Does the patient with myelofibrosis feel better through Pacritinib?
Vienna, June 12, 2015 –Dr Mesa will present new data from the phase 3 PERSIST-1 study on improving disease symptoms and quality of life for patients with myelofibrosis.
First randomized evidence for kinase inhibitor activity in acute myeloid leukemi…
Vienna, June 12, 2015 – Dr Ehninger will present the results of a phase II randomized study on the safety and efficacy of Sorafenib.
The European Union must deliver funding for research of blood disorders
At the Congress of the European Hematology Association (EHA) – attracting 10,000 hematologists from Europe and beyond - the president of EHA, Prof. Christine Chomienne, called upon the European Union to deliver funding for Research into Blood Disorders:
“The hematologists in Europe have done a great work. Now it’s the EU’s turn to deliver.”